Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
With weight reduction, GLP-1RA can improve dysregulated lipid profile and insulin resistance of individuals with obesity, thus reducing residual ASCVD risk [83,84,85]
Limited Long-Term Data on Maintenance Although early results are promising, questions remain about the long-term safety, efficacy, and cost-effectiveness of GLP-1s when used for weight loss rather than diabetes
Improves Metabolic Health A healthy diet not only supports weight loss and blood sugar control, but it also promotes better metabolic health
Clinical trials such as the STEP program (semaglutide) and SURMOUNT trials (tirzepatide) demonstrate that patients typically experience reduced caloric intake, with many reporting decreased interest in food and smaller portion sizes
Comparison of severity and frequency of side effects between semaglutide and Ozempic Since compounded semaglutide is not FDA-approved, the frequency and severity of side effects may vary depending on the formulation and individual response
In this session, your BMI, medical history, and weight loss goals are assessed to choose the most fitting treatment
